Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

被引：0

作者：

David F. McDermott

Mahrukh A. Huseni

Michael B. Atkins

Robert J. Motzer

Brian I. Rini

Bernard Escudier

Lawrence Fong

Richard W. Joseph

Sumanta K. Pal

James A. Reeves

Mario Sznol

John Hainsworth

W. Kimryn Rathmell

Walter M. Stadler

Thomas Hutson

Martin E. Gore

Alain Ravaud

Sergio Bracarda

Cristina Suárez

Riccardo Danielli

Viktor Gruenwald

Toni K. Choueiri

Dorothee Nickles

Suchit Jhunjhunwala

Elisabeth Piault-Louis

Alpa Thobhani

Jiaheng Qiu

Daniel S. Chen

Priti S. Hegde

Christina Schiff

Gregg D. Fine

Thomas Powles

机构：

[1] Beth Israel Deaconess Medical Center,

[2] Genentech,undefined

[3] Inc.,undefined

[4] Georgetown Lombardi Comprehensive Cancer Center,undefined

[5] Memorial Sloan Kettering Cancer Center,undefined

[6] Cleveland Clinic Taussig Cancer Institute,undefined

[7] Gustave Roussy,undefined

[8] University of California,undefined

[9] San Francisco School of Medicine,undefined

[10] Mayo Clinic Hospital –Florida,undefined

[11] City of Hope Comprehensive Cancer Center,undefined

[12] Florida Cancer Specialists,undefined

[13] Yale School of Medicine,undefined

[14] Sarah Cannon Research Institute,undefined

[15] Vanderbilt University Medical Center,undefined

[16] University of Chicago Medicine,undefined

[17] Texas Oncology – Baylor Charles A. Sammons Cancer Center,undefined

[18] Royal Marsden Hospital,undefined

[19] CHU Hopitaux de Bordeaux – Hôpital Saint-André,undefined

[20] Ospedale San Donato,undefined

[21] Azienda USL Toscana Sudest,undefined

[22] Vall d’Hebron Institute of Oncology,undefined

[23] Vall d’Hebron University Hospital,undefined

[24] Universitat Autònoma de Barcelona,undefined

[25] Azienda Ospedaliera Universitaria Senese,undefined

[26] Center for Immune-Oncology,undefined

[27] Medizinische Hochschule,undefined

[28] Zentrum Innere Medizin,undefined

[29] Abt. Hämatologie u. Onkologie,undefined

[30] Dana-Farber Cancer Institute,undefined

[31] Roche Products Ltd,undefined

[32] Barts Cancer Institute and the Royal Free Hospital,undefined

[33] Queen Mary University of London,undefined

来源：

Nature Medicine | 2018年 / 24卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

In the version of this article originally published, there was an error in Fig. 2n. The top line of the HR comparison chart originally was Atezo + bev vs sun. It should have been Atezo + bev vs atezo. The error has been corrected in the HTML and PDF versions of this article.

引用

页码：1941 / 1941

共 50 条

[41] Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma.
Lee, Chung-Han
Motzer, Robert J.
Hoetker, Andreas
Akin, Oguz
Molina, Ana M.
Gold, Theresa Margaret
Patil, Sujata
Janakiraman, Manickam
Gowrishankar, Banumathy
Houldsworth, Jane
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[42] Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Rini, Brian I.
Powles, Thomas
Atkins, Michael B.
Escudier, Bernard
McDermott, David F.
Suarez, Cristina
Bracarda, Sergio
Stadler, Walter M.
Donskov, Frede
Lee, Jae Lyun
Hawkins, Robert
Ravaud, Alain
Alekseev, Boris
Staehler, Michael
Uemura, Motohide
De Giorgi, Ugo
Mellado, Begona
Porta, Camillo
Melichar, Bohuslav
Gurney, Howard
Bedke, Jens
Choueiri, Toni K.
Parnis, Francis
Khaznadar, Tarik
Thobhani, Alpa
Li, Shi
Piault-Louis, Elisabeth
Frantz, Gretchen
Huseni, Mahrukh
Schiff, Christina
Green, Marjorie C.
Motzer, Robert J.
LANCET, 2019, 393 (10189): : 2404 - 2415
[43] Atezolizumab (atezo) plus bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.
Rini, Brian I.
Motzer, Robert J.
Powles, Thomas
McDermott, David F.
Escudier, Bernard
Donskov, Frede
Hawkins, Robert E.
Bracarda, Sergio
Bedke, Jens
De Giorgi, Ugo
Porta, Camillo
Ravaud, Alain
Parnis, Francis
Grande, Enrique
Zhang, Wei
Huseni, Mahrukh A.
Carroll, Susheela
Sufan, Roxana Ioana
Schiff, Christina
Atkins, Michael B.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[44] CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma-Results of a phase III noninferiority trial.
Mejean, Arnaud
Escudier, Bernard
Thezenas, Simon
Beauval, Jean-Baptiste
Geoffroy, Lionnel
Bensalah, Karim
Thiery-Vuillemin, Antoine
Cormier, Luc
Lang, Herve
Guy, Laurent
Gravis, Gwenaelle
Rolland, Frederic
Linassier, Claude
Timsit, Marc Olivier
Albiges, Laurence
Beisland, Christian
Aitchison, Michael
Colas, Sandra
Lebret, Thierry
Ravaud, Alain
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
[45] Endothelial angiopoietin-2 expression correlates with tumor angiogenesis and response to sunitinib in metastatic renal cell carcinoma
Lampinen, Anita
Rautiola, Juhana
Mirtti, Tuomas
Ristimaki, Ari
Joensuu, Heikki
Bono, Petri
Saharinen, Pipsa
CANCER RESEARCH, 2015, 75
[46] Neoadjuvant effects in a randomized phase 2 study with a cell-based immune primer plus sunitinib versus sunitinib alone in patients with metastatic Renal Cell Carcinoma
Ljungberg, B.
Lindskog, M.
Karlsson-Parra, A.
SCANDINAVIAN JOURNAL OF UROLOGY, 2023, 58 : 31 - 32
[47] A phase I/II study to evaluate the safety, pharmacodynamics, and efficacy of entinostat in combination with atezolizumab and bevacizumab in patients with renal cell carcinoma.
Pili, Roberto
Haas, Naomi B.
Monk, Paul
Logan, Theodore F.
Narayan, Vivek
Burney, Heather
Adra, Nabil
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[48] Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Motzer, Robert J.
Powles, Thomas
Atkins, Michael B.
Escudier, Bernard
McDermott, David F.
Alekseev, Boris Y.
Lee, Jae-Lyun
Suarez, Cristina
Stroyakovskiy, Daniil
De Giorgi, Ugo
Donskov, Frede
Mellado, Begona
Banchereau, Romain
Hamidi, Habib
Khan, Omara
Craine, Veronica
Huseni, Mahrukh
Flinn, Nick
Dubey, Sarita
Rini, Brian, I
JAMA ONCOLOGY, 2022, 8 (02) : 275 - 280
[49] A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)
John D. Hainsworth
James A. Reeves
Joseph R. Mace
Edward J. Crane
Oday Hamid
John R. Stille
Amy Flynt
Stephanie Roberson
John Polzer
Edward R. Arrowsmith
Targeted Oncology, 2016, 11 : 643 - 653
[50] A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)
Hainsworth, John D.
Reeves, James A.
Mace, Joseph R.
Crane, Edward J.
Hamid, Oday
Stille, John R.
Flynt, Amy
Roberson, Stephanie
Polzer, John
Arrowsmith, Edward R.
TARGETED ONCOLOGY, 2016, 11 (05) : 643 - 653

← 1 2 3 4 5 →